Mangalam Drugs loan default: ₹15.58 crore due in 2026

Overview of the disclosure

Mangalam Drugs and Organics Ltd has disclosed a default on its loan obligations to Bank of Maharashtra and Bank of Baroda, with overdue dues aggregating more than ₹15.57 crore. The disclosure was made through a regulatory filing, with the company stating it is reporting the matter under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. That regulation requires listed entities to inform stock exchanges when a default on debt obligations continues beyond 30 days. The company’s filing indicates that the overdue amounts relate to cash credit facilities with the two banks. The defaults date back to October 2025 and have continued for several months beyond the 30-day reporting threshold.

What the company reported to exchanges

In its intimation, Mangalam Drugs said the overdue amount with Bank of Maharashtra stood at ₹9.51 crore on its cash credit account. The filing cited that the default on this Bank of Maharashtra facility commenced on October 17, 2025. Separately, the company reported overdue dues of ₹6.06 crore to Bank of Baroda, with the default dating back to October 20, 2025. Taken together, these two overdues add up to roughly ₹15.57 crore to ₹15.58 crore, based on the figures provided in different parts of the disclosed information.

The company also stated it is making arrangements to clear the overdue amounts “as soon as possible.” However, the information provided does not include a specific repayment timeline or a detailed schedule for curing the defaults. The disclosures emphasise that the defaults have persisted, indicating ongoing stress around servicing these working-capital facilities.

Dates and reference points mentioned in the filing

The disclosure includes multiple “as of” dates across subsequent intimations. One reference states that as of June 15, 2026, the overdue amount with Bank of Maharashtra was INR 95.197 million and with Bank of Baroda was INR 60.608 million. These amounts correspond to ₹9.5197 crore and ₹6.0608 crore respectively. Another reference point states that as of July 15, 2026, the company had an overdue amount of ₹9.51 crore with Bank of Maharashtra and ₹6.06 crore with Bank of Baroda.

The narrative across these dates is consistent on two core facts: the defaults are on cash credit accounts with the two banks and the start dates of default are in October 2025. The reporting is positioned as a continuing status update under SEBI’s disclosure requirements.

Why Regulation 30 matters here

Regulation 30 of SEBI (LODR) is designed to ensure timely and uniform disclosure of material events, including debt defaults that extend beyond 30 days. For investors and lenders, such disclosures act as a public signal that scheduled servicing obligations have not been met within the stipulated period. In this case, the company explicitly tied its disclosure to the requirement for reporting defaults that exceed 30 days.

The information shared suggests the default status has remained unresolved for an extended period. While the company has stated it is arranging funds to clear the dues, the absence of a specific timeline means the market has limited visibility on when the accounts may be regularised.

The backstory: defaults starting October 2025

Mangalam Drugs’ filings indicate that the first date of default for Bank of Maharashtra was October 17, 2025. For Bank of Baroda, the default start date was October 20, 2025. The continued reference to these dates across later updates implies that the overdues have not been fully cleared since those dates.

The disclosures also repeatedly describe the facilities as cash credit. Cash credit is typically a working-capital line used to fund operations, inventory, and receivables. Persistent overdues on such facilities can raise concerns around liquidity management, particularly when the default continues beyond regulatory reporting thresholds.

Key figures at a glance

What changes now for stakeholders

From an investor perspective, the continuing default disclosure primarily improves transparency about the company’s debt servicing position rather than providing a resolution. The company’s statement that it is making arrangements to clear overdues indicates intent, but the lack of a repayment timeline limits the ability to assess near-term outcomes.

For lenders and counterparties, the disclosure confirms that the overdue amounts have crossed the 30-day default threshold and have continued since October 2025. For customers and suppliers, such filings can prompt closer scrutiny of the company’s working-capital cycle, especially when cash credit lines are involved.

Market impact (as supported by the filing)

The direct market-relevant fact in the disclosure is the quantum and duration of overdue obligations: more than ₹15.57 crore across two bank cash credit accounts, with defaults beginning in October 2025. The filing also makes clear that the event meets SEBI’s material disclosure threshold for defaults beyond 30 days. The regulatory nature of the disclosure means the information is intended to be price-sensitive and widely disseminated.

Beyond those points, the company has not provided additional quantified impacts, such as changes to interest rates, penal charges, restructuring terms, or revised repayment schedules. As a result, any assessment of broader financial effects should be limited to the confirmed overdue amounts, the banks involved, and the stated persistence of default.

Analysis: what the persistence indicates

The repeated subsequent intimations and unchanged default start dates indicate that the overdues have persisted across multiple reporting points. The consistency in the reported amounts for Bank of Maharashtra (around ₹9.52 crore) and Bank of Baroda (around ₹6.06 crore) suggests that a significant portion of the overdue balance remained outstanding during the period covered.

The filing’s emphasis on “arrangements” without a timeline also signals that the resolution process is still in progress. For readers tracking credit events, the most important verified detail is that the default has extended well past the initial 30-day threshold and remains disclosed as ongoing.

Conclusion

Mangalam Drugs and Organics has reported continuing defaults on cash credit facilities with Bank of Maharashtra and Bank of Baroda, with total overdue dues of roughly ₹15.57 crore to ₹15.58 crore and default start dates in October 2025. The company has said it is arranging to clear the overdues as soon as possible, but it has not provided a specific repayment timeline in the disclosed information. Further clarity, if any, is likely to come through subsequent exchange filings as the status of the overdue accounts changes.